The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rekhtina I.G.

Gematologicheskiĭ nauchnyĭ tsentr Ministerstva zdravookhraneniia Rossii

Mendeleeva L.P.

GNTs Minzdrava Rossii, Moskva

Current approaches to treating of patients with multiple myeloma with renal failure: Questions and proofs

Authors:

Rekhtina I.G., Mendeleeva L.P.

More about the authors

Journal: Therapeutic Archive. 2017;89(7): 112‑117

DOI: 10.17116/terarkh2017897112-117

Read: 3693 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT APPROACHES TO TREATING OF PATIENTS WITH MULTIPLE MYELOMA WITH RENAL FAILURE: QUESTIONS AND PROOFS
CURRENT APPROACHES TO TREATING OF PATIENTS WITH MULTIPLE MYELOMA WITH RENAL FAILURE: QUESTIONS AND PROOFS

To cite this article:

Rekhtina IG, Mendeleeva LP. Current approaches to treating of patients with multiple myeloma with renal failure: Questions and proofs. Therapeutic Archive. 2017;89(7):112‑117. (In Russ.)
https://doi.org/10.17116/terarkh2017897112-117

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Renal failure (RF) is detected in 20-30% of patients at the onset of multiple myeloma (MM), in 50% of patients during its progression. The advent of new, highly effective agents has considerably expanded the possibilities of treatment in MM patients. Unfortunately, patients with RF, especially those with severe RF, were not included in the majority of investigations. The available data are based on the results of treatment in small groups of patients generally without the morphological identification of nephropathies, with varying severity of RF, which explains significant differences in renal response rates. This review analyzes the results of the most important studies and gives recommendations for treatment in accordance with national and international standards.

Keywords:

multiple myeloma
renal failure

Authors:

Rekhtina I.G.

Gematologicheskiĭ nauchnyĭ tsentr Ministerstva zdravookhraneniia Rossii

Mendeleeva L.P.

GNTs Minzdrava Rossii, Moskva

Close metadata

References:

  1. Solovjev MV, Mendeleeva LP, Pokrovskaja OS, Gribanova EO, Nakastoev IM, Gemdjan EG, Voloditcheva EM, Antchukova LV, Frolova MV, Menshakova SN, Ocjunihina SM, Mashnina NN, Voicehovskii VV, Filatova EA, Beljaeva SS, Borisenkova EA, Verhogljad IS, Mostovaja VS, Voronova EV, Lapin VA, Gvasdarjeva AS, Gricenko TA, Davidova GA, Kalinovskaja EU, Cinchenko JD, Kirillova EG, Kaplanov KD, Kaporskaja TS, Kiseleva MJ, Konstantinova TS, Ksenova TI, Shakirov II, Martinova EV, Mihalev MA, Patrakovva EV, Popova NB, Pospelova TI, Rachkova NN, Savinova MT, Samojlova OS, Morosov DN, Alekseeva AN, Sitcheva TM, Tarasenkova EV, Savchenko VG. Epidemiology of multiple myeloma in Russia (results of a multicenter study). Hematology and transfusiology. Gematologiya i transfusiologiya. 2016;61(1,Suppl.1):28. (In Russ.)
  2. Mendeleeva LP, Votyakova OM, Pokrovskaya OS, Rekhtina IG, Darskaya EI, Galtseva IV, Kaplanov KD, Motorin DV, Samoylova OS, Semochkin SV, Skvortsova NV, Soloviev MV, Urnova ES, Savchenko VG. National clinical recommendations on diagnosis and treatment of multiple myeloma. Hematology and Transfusiology. Gematologiya i transfusiologiya. 2016;61(1,Suppl.2):1-24. (In Russ.)https://doi.org/10.18821/0234-5730-2016-61-1
  3. Dimopoulos M, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, Goldschmidt H, Joshua D, Orlowski R, Powles R, Vesole D, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson P, Moreau P, San Miguel J, Rajkumar S, Durie B, Terpos E. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016;34:1544-1557. https://doi.org/10.1200/JCO.2015.65.0044
  4. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000; 65(3):175-181.
  5. Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, Autzinger E, Heintel D, Greil R, Poenisch W, Muldur E, Zojer N. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica. 2014;100:385-391. https://doi.org/10.3324/haematol.2014.115204
  6. Uttervall K, Duru A, Lund J, Liwing J, Gahrton G, Holmberg E, Aschan J, Alici E, Nahi H. The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment. PLoS ONE. 2014;9:e101819. https://doi.org/10.1371/journal.pone.0101819
  7. Gonsalves W, Leung N, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F, Dingli D, Kapoor P, Go R, Lin Y, Russell S, Lust J, Zeldenrust S, Kyle R, Gertz M, Kumar S. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015;5:e296. https://doi.org/10.1038/bcj.2015.20
  8. Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, Lacy M, Dispenzieri A, Rajkumar SV, Kyle RA, Leung N. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786-794. https://doi.org/10.1053/j.ajkd.2011.12.028
  9. Rekhtina IG, Mendeleeva LP, Biriukova LS. Dialysis-dependent renal failure in patients with multiple myeloma: Reversibility factors. Ter Arkh. 2015;7:72-76. (In Russ.)
  10. Hutchison C, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012;27:3823-3828. https://doi.org/10.1093/ndt/gfr773
  11. Ecotière L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Goujon J, Fermand J, Touchard G, Bridoux F. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant. 2015;31:64-72. https://doi.org/10.1093/ndt/gfw056
  12. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, Dimopoulos M. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymph. 2008;49:890-895. https://doi.org/10.1080/10428190801930506
  13. Morabito F, Gentile M, Ciolli S, Petrucci M, Galimberti S, Mele G, Casulli A, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European J Haematol. 2010;84:223-228. https://doi.org/10.1111/j.1600-0609.2009.01385
  14. Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F, Autzinger E, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010;28:4635-4641. https://doi.org/10.1200/JCO.2010.28.1238
  15. Dimopoulos M, Richardson P, Schlag R, Khuageva N, Shpilberg O, Kastritis E, Kropff M, Petrucci M, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos M, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel J. VMP (Bortezomib, Melphalan, and Prednisone) Is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA Study. J Clin Oncol. 2009;27:6086-6093. https://doi.org/10.1200/JCO.2009.22.2232
  16. Dimopoulos M, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastritis E. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91:499-502. https://doi.org/10.1002/ajh.24335
  17. Scheid C, Sonneveld P, Schmidt-Wolf I, van der Holt B, Jarari L, Bertsch U, Salwender H, Zweegman S, Blau I, Vellenga E, Weisel K, Pfreundschuh M, Jie K, Neben K, van de Velde H, Duehrsen U, Schaafsma M, Lindemann W, Kersten M, Peter N, Hanel M, Croockewit S, Martin H, Wittebol S, Bos G, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst H. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica. 2013;99:148-154. https://doi.org/10.3324/haematol.2013.087585
  18. Rekhtina IG, Mendeleeva LP, Varlamova EYu., Biriukova LS. Sravnenie effectivnosty bortesomibsodergachih program v dostigenii rannego gematologicheskogo i pochechnogo otveta u bolnih mielomnoi nephropatiey s dialissavisimoj pochechnoj nedostatochnostju. [Comparison of the efficiency of bortezomib-based protocols in induction of an early hematological and renal response in myeloma nephropathy patients with hemodialysis-dependent renal failure]. Hematology and transfusiology. Gematologiya I transfusiologiya. 2015;60(4):4-7. (In Russ.)
  19. Cohen Y, Joffe E, Benyamini N, Dimopoulos M, Terpos E, Trestman S, Held-Kuznetsov V, Avivi I, Kastritis E. Primary failure of bortezomib in newly diagnosed multiple myeloma — understanding the magnitude, predictors, and significance. Leuk Lymph. 2016;57:1382-1388. https://doi.org/10.3109/10428194.2015.1121258
  20. Dimopoulos M, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leuk. 2012;27:423-429. https://doi.org/10.1038/leu.2012.182
  21. Ludwig H, Kasparu H, Müldür E, Zojer N. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica. 2015;100(3):385-391. https://doi.org/10.3324/haematol.2014.115204
  22. Leung N, Gertz M, Zeldenrust S, Rajkumar S, Dispenzieri A, Fervenza F, Kumar S, Lacy M, Lust J, Greipp P, Witzig T, Hayman S, Russell S, Kyle R, Winters J. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Intern. 2008;73:1282-1288. https://doi.org/10.1038/ki.2008.108
  23. Hutchison C, Bradwell A, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans N, Chappel M, Sampson P, Foggensteiner L, Adu D, Cockwell P. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Society Nephrol. 2009;4:745-754. https://doi.org/10.2215/CJN.04590908
  24. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM) Multiple Myeloma Version 3.2016 http://www.NCCN.org
  25. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen H, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist U, Chng W, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim C, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski R, Miguel J, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia. 2015;30:1005-1017. https://doi.org/10.1038/leu.2015.356
  26. Petrucci M, Giraldo P, Corradini P, Teixeira A, Dimopoulos M, Blau I, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013;160:649-659. https://doi.org/10.1111/bjh.12198
  27. Knopf K, Duh M, Lafeuille M, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo R. Meta-Analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma and Leuk. 2014;14:380-388. https://doi.org/10.1016/j.clml.2014.03.005
  28. San-Miguel J, Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau J, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh J, Neuwirth R, Boral A, Esseltine D, Anderson K. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22:842-849. https://doi.org/10.1038/sj.leu.2405087
  29. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ; Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment. DOXIL-MMY-3001 Study Investigators. Clin Lymphoma Myeloma. 2008.8(6):352-355. https://doi.org/10.3816/CLM.2008.n.051
  30. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM.The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116(16):3807-3814. https://doi.org/10.1002/cncr.25139
  31. Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P;Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25:749-760. https://doi.org/10.1038/leu.2011.3
  32. Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90(4):429-439. https://doi.org/10.1007/s00277-010-1080-4
  33. Zhou DB, Yu L, Du X, Jin J, Cai Z, Chen F, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, DeMarco D, Chen N, Mei J, Wang J, Hou J.Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int J Hematol. 2015;101(6):569-577. https://doi.org/10.1007/s12185-015-1771-7
  34. João C, Freitas J, Gomes F, Geraldes C, Coelho I, Neves M, Lúcio P, Esteves S, Esteves GVLenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment. Ann Hematol. 2016;95(6):931-936. https://doi.org/10.1007/s00277-016-2662-6
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.